Sanofi and Regeneron teamed up in a second major deal, focused on immuno-oncology; after an unsuccessful try at Mylan, Teva bought Allergan's generics business. Between June and July, biopharma companies raised over $10 billion, and device firms more than $1 billion.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.